
Meta-analysis of 85 randomized trials and 70,543 patients links SGLT2 inhibitors to small increases in hemoglobin and erythropoietin
AI-summarized from the linked source. Educational brief, not medical advice.
Brief summary
A systematic review and meta-analysis of 85 randomized controlled trials encompassing 70,543 participants found that SGLT2 inhibitor therapy was associated with small, statistically significant increases in hemoglobin (+0.60 g/dL), hematocrit (+2.36%), and erythropoietin (+2.11 mIU/mL).
What NurseJet pulled from the source
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely prescribed across chronic heart failure, type 2 diabetes, and chronic kidney disease, where retrospective observations frequently note concurrent elevations in red blood cell indices. In this systematic review and meta-analysis searching PubMed, Web of Science, and CENTRAL through July 22, 2026, researchers pooled data from 85 double-masked randomized clinical trials (median duration 24 weeks; IQR 12–32 weeks) covering 70,543 patients (mean age 62.4 +/- 9.4 years; 35.9% female). Seventy-eight trials compared SGLT2 inhibitors against placebo, and seven utilized active comparators (primarily sitagliptin). From baseline to follow-up, hemoglobin increased by 0.55 g/dL with SGLT2 inhibitors versus a 0.08 g/dL decrease in control cohorts (net between-group difference 0.60 g/dL, 95% CI: 0.55–0.66 g/dL; p < 0.001). Hematocrit changed by +2.17% versus -0.13% in controls (difference 2.36%, 95% CI: 2.19%–2.52%; p < 0.001). Analysis of secondary erythropoietic and iron parameters demonstrated a significant increase in serum erythropoietin (difference 2.11 mIU/mL, 95% CI: 0.50–3.71; p = 0.01) and a significant reduction in transferrin saturation (difference -0.84%, 95% CI: -1.21% to -0.47%; p < 0.001).
Why this matters for nurses
Nurses administer SGLT2 inhibitors (such as empagliflozin, dapagliflozin, and canagliflozin) daily on medical-surgical, cardiac, and renal units. When reviewing routine complete blood count panels, nurses observing slight elevations in hemoglobin or hematocrit must recognize this as a known physiologic class effect mediated by hemoconcentration and mild erythropoietin stimulation, rather than misinterpreting it as acute dehydration or treating SGLT2 inhibitors as an anemia cure.
Bedside takeaway
In a meta-analysis of 85 RCTs and 70,543 patients, SGLT2 inhibitors led to small increases in hemoglobin (+0.60 g/dL) and erythropoietin (+2.11 mIU/mL), though clinical significance is unclear.
Key takeaways
- Systematic review analyzed 85 double-masked RCTs encompassing 70,543 patients across cardiology, nephrology, and endocrinology.
- SGLT2 inhibitors produced modest but statistically significant increases in hemoglobin (+0.60 g/dL) and hematocrit (+2.36%).
- Therapy was associated with stimulated erythropoiesis, evidenced by an increase in serum erythropoietin (+2.11 mIU/mL, p = 0.01).
- Transferrin saturation decreased slightly (-0.84%, p < 0.001), reflecting increased iron utilization during erythropoiesis.
- Authors emphasized that clinical significance remains uncertain and SGLT2 inhibitors should not be prescribed for the primary intent of treating anemia.
Practice implications
- Anticipate modest increases in hemoglobin and hematocrit when monitoring patients on SGLT2 inhibitors; differentiate expected class-related hemoconcentration and erythropoietin stimulation from acute volume depletion, and continue reinforcing fluid balance and medication adherence.
Limitations & cautions
- The observed hematologic elevations were small (+0.60 g/dL hemoglobin), and the clinical importance of these changes remains unproven; trials were not designed to test clinical anemia endpoints or symptomatic benefit; SGLT2 inhibitors are not approved for anemia therapy.
- AI-summarized from the linked source. Review the original article before applying to practice.
Citations
Exact source links
Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.
JAMA (PubMed)
JAMA (PubMed). Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
https://pubmed.ncbi.nlm.nih.gov/42925557/
Professional education only


